A modified pharmaceutical excipient derived from Chinese herbal medicine polysaccharide fiber and its preparation method

By using a rigid-flexible structured bridging citric acid crosslinking agent, the wet stability and flexibility issues of Astragalus polysaccharide/polyvinyl alcohol fiber materials were resolved, improving the structural stability and mechanical properties of the fiber membrane and enhancing its biocompatibility.

CN123101686APending Publication Date: 2026-11-17NANYANG CHUANJING DIGITAL INTELLIGENCE TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611426261.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the existing technology, astragalus polysaccharide/polyvinyl alcohol fiber materials have insufficient structural stability in the wet state, and the material flexibility is reduced when cross-linked with small molecule polycarboxylic acids, making it difficult to meet the requirements for material flexibility and compliance in scenarios such as wound dressings.

Method used

A rigid-flexible structured bridging citric acid crosslinking agent is used, with triazine rings as rigid connecting units and glycol chains as flexible bridging units, to crosslink with hydroxyl groups in the molecular chains of astragalus polysaccharide and polyvinyl alcohol, forming a stable crosslinking network.

Benefits of technology

It improves the structural stability and mechanical properties of fiber membranes in aqueous media, enhances the flexibility and biocompatibility of materials, reduces the solubility, and improves the tensile strength and elongation at break.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
Patent Text Reader

Abstract

This invention relates to the field of pharmaceutical excipients technology, and discloses a herbal polysaccharide fiber composite modified pharmaceutical excipient and its preparation method. The herbal polysaccharide fiber composite modified pharmaceutical excipient is a cross-linked astragalus polysaccharide / polyvinyl alcohol fiber membrane, which is prepared from the following raw materials in parts by weight: 10-20 parts astragalus polysaccharide, 70-85 parts polyvinyl alcohol, 3-8 parts rigid-flexible structured bridging citric acid crosslinking agent, and 900-1100 parts deionized water. This invention uses citric acid as the crosslinking unit, triazine rings as rigid connecting units, and glycol chains of different chain lengths as flexible bridging units to construct a rigid-flexible structured bridging citric acid crosslinking agent. This agent is then blended with astragalus polysaccharide and polyvinyl alcohol, and the resulting material is prepared by electrospinning and vacuum thermal crosslinking processes to obtain the herbal polysaccharide fiber composite modified pharmaceutical excipient. This achieves the beneficial technical effect of synergistic optimization of the safety, stability, and flexibility of the polysaccharide fiber excipient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical excipients technology, specifically to a Chinese herbal medicine-derived polysaccharide fiber composite modified pharmaceutical excipient and its preparation method. Background Technology

[0002] Pharmaceutical excipients are a core component of drug formulations, not only giving drugs specific dosage forms but also directly affecting their stability, drug release behavior, and bioavailability. Among them, micro / nano-fiber pharmaceutical excipients, due to their high specific surface area, high porosity, and strong structural designability, can mimic the microstructure of the natural extracellular matrix and show broad application prospects in wound dressings, drug carriers, and mucosal adhesion materials.

[0003] Astragalus polysaccharide is one of the main active ingredients extracted from the traditional Chinese medicine Astragalus membranaceus. Its molecular chain is rich in hydroxyl groups, exhibiting good biocompatibility and biodegradability. However, astragalus polysaccharide has a wide molecular weight distribution and poor solution rheological properties, making it difficult to process into molding compounds alone. Polyvinyl alcohol (PVA) is a water-soluble synthetic polymer with good fiber-forming properties, biocompatibility, and non-toxicity, and has been widely recognized as a standard excipient in various pharmaceutical preparations. PVA is often blended with natural polysaccharides as a backbone polymer, utilizing the hydrogen bond interactions formed by the abundant hydroxyl groups between the two molecules to improve the compatibility of the blend system and the spinnability of the polysaccharide, thereby enhancing the mechanical properties of the fiber. However, both astragalus polysaccharide and PVA are water-soluble polymers. Fibers obtained through physical blending alone are prone to swelling or dissolving in body fluids, exhibiting insufficient wet stability and difficulty in maintaining the integrity of the fiber structure. Therefore, cross-linking modification is usually required to form a covalent bond network between molecules, improving the fiber's water resistance, mechanical strength, and structural stability.

[0004] In the existing technology, crosslinking agents used in polysaccharide / PVA fiber systems are mainly divided into two categories: one is small molecule crosslinking agents such as glutaraldehyde and epichlorohydrin, which have high crosslinking activity and efficiency, but pose a risk of toxic residues and have poor biocompatibility, making it difficult to meet the safety standards for pharmaceutical excipients; the other is natural polycarboxylic acid crosslinking agents such as citric acid and tartaric acid, which have high biocompatibility, but due to their small molecular weight, short molecular chain segments, and relatively high network rigidity, the network formed after crosslinking is not flexible enough, which easily leads to low elongation at break of fiber membrane and decreased fatigue resistance, making it difficult to meet the requirements for material flexibility and compliance in scenarios such as wound dressings.

[0005] Therefore, how to develop a polysaccharide fiber crosslinking modification scheme that combines good biocompatibility, wet stability and flexibility remains a technical problem that urgently needs to be solved in this field. Summary of the Invention

[0006] This invention aims to address the problems of insufficient wet structural stability of Astragalus polysaccharide / polyvinyl alcohol fiber materials when relying solely on physical blending, and the reduced flexibility of materials when using small molecule polycarboxylic acids for crosslinking. It provides an Astragalus polysaccharide fiber composite modified pharmaceutical excipient and its preparation method.

[0007] This invention constructs a rigid-flexible structured bridging citric acid crosslinking agent. This crosslinking agent uses a triazine ring as a rigid connecting unit and a glycol chain as a flexible bridging unit, with multiple carboxyl-containing citric acid crosslinking units connected to the triazine ring. The triazine ring provides relatively stable structural connection nodes, the glycol chain increases the flexibility of the connecting segments in the crosslinking network, and the carboxyl groups in the citric acid structure react with the hydroxyl groups in the astragalus polysaccharide and / or polyvinyl alcohol molecular chains under heating conditions to undergo a crosslinking reaction.

[0008] In the preparation process, astragalus polysaccharide and polyvinyl alcohol are first dissolved in water, and then mixed with the rigid-flexible structured bridging citric acid crosslinking agent to form a composite spinning solution; astragalus polysaccharide / polyvinyl alcohol fiber precursor is formed by electrospinning; then crosslinking treatment is carried out under vacuum heating conditions to form a crosslinking network inside the fiber, thereby improving the structural stability of the obtained fiber membrane in the aqueous medium and improving its mechanical properties.

[0009] By changing the length of the glycol chain in the bridging crosslinking agent, the spacing between adjacent rigid connecting nodes and the flexibility of the chain segments in the crosslinking network can be adjusted. Experimental results of this invention show that when tetraethylene glycol, hexaethylene glycol, and octaethylene glycol are used as flexible bridging units, the swelling properties, dissolution resistance, tensile strength, and elongation at break of the resulting fiber membrane exhibit adjustable variations.

[0010] A herbal polysaccharide fiber composite modified pharmaceutical excipient, wherein the herbal polysaccharide fiber composite modified pharmaceutical excipient is a cross-linked astragalus polysaccharide / polyvinyl alcohol fiber membrane, which is prepared from the following raw materials in parts by weight:

[0011] 10-20 parts of Astragalus polysaccharide;

[0012] 70-85 parts polyvinyl alcohol;

[0013] 3-8 parts of rigid-flexible structured bridging citric acid crosslinking agent;

[0014] 900-1100 parts deionized water;

[0015] Preferably, the purity of the astragalus polysaccharide is >90%.

[0016] Preferably, the polyvinyl alcohol is of type 1788.

[0017] A method for preparing a modified pharmaceutical excipient made from polysaccharide fibers derived from traditional Chinese medicine includes the following steps:

[0018] Step 1: Vacuum dry, pulverize and sieve the astragalus polysaccharide, and pulverize and sieve the polyvinyl alcohol for later use;

[0019] Step 2: Add polyvinyl alcohol to 65-75 wt% of the total formula amount of deionized water, heat and stir to dissolve, and cool to obtain PVA aqueous solution; add astragalus polysaccharide to the remaining amount of the formula amount of deionized water, heat and stir to dissolve, filter, and cool to obtain astragalus polysaccharide aqueous solution; add astragalus polysaccharide aqueous solution to PVA aqueous solution and mix well, then add rigid-flexible structured bridging citric acid crosslinking agent, stir and mix, and let stand to degas to obtain composite spinning solution;

[0020] Step 3: Electrospin the composite spinning solution, and after spinning, vacuum dry the collected fiber membrane to obtain the fiber precursor.

[0021] Step 4: The fiber precursor is thermally cross-linked under vacuum conditions, cooled, and post-treated to obtain a cross-linked Astragalus polysaccharide / polyvinyl alcohol fiber membrane, which is a modified pharmaceutical excipient made from polysaccharide fiber derived from traditional Chinese medicine.

[0022] Preferably, the preparation method of the rigid-flexible structured bridging citric acid crosslinking agent is as follows:

[0023] Using 1 molar equivalent of cyanuric chloride and 1.95-1.99 molar equivalent of methyl citrate as raw materials, in a NaH / THF reaction system, taking advantage of the difference in the activity of the chlorine groups in cyanuric chloride, a stepwise substitution reaction is carried out between the hydroxyl group of methyl citrate and the two chlorine groups in cyanuric chloride to obtain a dimethyl citrate type monochlorotriazine intermediate.

[0024] Using 2.01-2.05 molar equivalents of dimethyl citrate-type monochlorotriazine intermediate and 1 molar equivalent of glycol monomer as raw materials, in a NaH / THF reaction system, a rigid-flexible structured bridged methyl citrate compound was obtained by substitution reaction between the hydroxyl group of the glycol monomer and the chlorine group in the dimethyl citrate-type monochlorotriazine intermediate.

[0025] Using rigid-flexible structured bridging methyl citrate as raw material, the methyl citrate groups are first saponified in a NaOH / H2O / ethanol reaction system to convert them into the corresponding sodium citrate salt. Then, hydrochloric acid is used to acidify the sodium citrate salt to convert it into citric acid groups, thus obtaining a rigid-flexible structured bridging citric acid crosslinking agent.

[0026] Preferably, the glycol monomer is one of tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, heptaethylene glycol, and octaethylene glycol.

[0027] Preferably, in step two: polyvinyl alcohol is stirred and dissolved at 85-95℃ for 1.5-2.5h; astragalus polysaccharide is stirred and dissolved at 45-55℃ for 0.8-1.2h.

[0028] Preferably, the electrospinning process parameters in step three are: voltage 16-20kV, receiving distance 15-20cm, feed speed 0.6-1.0mL / h, ambient temperature 23℃-28℃, and relative humidity 50-60%.

[0029] Preferably, the process parameters for the thermal crosslinking treatment in step four are: heating to 115-125℃ at a rate of 1.5-2.5℃ / min and holding at that temperature for 2.5-4 hours.

[0030] Preferably, the process parameters for cooling and post-processing in step four are as follows: first, cool down to 23℃-28℃ at a rate of 1-1.5℃ / min, and then place in an environment with a temperature of 23℃-28℃ and a relative humidity of 50-60% for equilibration for 20-30 hours.

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] Compared to the astragalus polysaccharide / polyvinyl alcohol fiber membrane without crosslinking agent, the fiber membrane obtained by treatment with the rigid-flexible structured bridging citric acid crosslinking agent of this invention exhibits a significantly reduced 24-hour solubility in PBS buffer at 37°C and pH=7.4. Under the test conditions described in this specification, the 24-hour solubility of fiber membranes prepared using crosslinking agents M-4, M-6, and M-8 were 5.89%, 6.41%, and 6.96%, respectively, while the comparative sample without crosslinking agent showed a solubility of 34.72%, indicating that crosslinking treatment can improve the wet structural stability of the fiber membrane.

[0033] The tensile strengths of the fiber membranes obtained using crosslinking agents M-4, M-6, and M-8 were 8.15 MPa, 7.73 MPa, and 7.20 MPa, respectively, with elongations at break of 70.8%, 89.2%, and 102.5%, respectively. Compared with the 25.3% elongation at break of the control group using small-molecule citric acid crosslinking, the bridging crosslinking agents were beneficial in improving the deformability of the obtained fiber membranes. With the increase of glycol bridging chain length, the obtained materials showed a trend of gradually decreasing tensile strength and gradually increasing elongation at break, indicating that the mechanical properties of the material can be adjusted by changing the bridging chain length.

[0034] Under the L929 cell extract test conditions used in this specification, the relative cell viability of samples prepared using M-4, M-6, and M-8 crosslinking agents were 98.5%, 99.1%, and 98.7%, respectively; under the rabbit skin irritation test conditions, no obvious irritation reaction was observed. These results indicate that the material has good preliminary biocompatibility under the test conditions specified in this specification, but do not replace a complete safety evaluation required for a specific pharmaceutical use. Detailed Implementation

[0035] Experimental example:

[0036] The rigid-flexible structured bridging citric acid crosslinking agent is prepared by the following steps:

[0037] Step 1: Preparation of dimethyl citrate-type monochlorotriazine intermediate: Using cyanuric chloride (1 eq) and methyl citrate (1.98 eq) as raw materials, in a NaH / THF reaction system, utilizing the difference in activity of the chlorine groups in cyanuric chloride, a stepwise substitution reaction occurs between the hydroxyl group of methyl citrate and the two chlorine groups in cyanuric chloride to obtain the dimethyl citrate-type monochlorotriazine intermediate. Its chemical structural formula is as follows:

[0038] ;

[0039] Where R' is ;

[0040] Step 2: Preparation of rigid-flexible structured bridged methyl citrate compound: Using a dimethyl citrate-type monochlorotriazine intermediate (2.04 eq) and a glycol monomer (1 eq) as raw materials, in a NaH / THF reaction system, a rigid-flexible structured bridged methyl citrate compound is obtained through a substitution reaction between the hydroxyl group of the glycol monomer and the chlorine group of the dimethyl citrate-type monochlorotriazine intermediate. Its chemical structure is as follows:

[0041] ;

[0042] Where R' is ;

[0043] Step 3: Preparation of rigid-flexible structured bridged citric acid crosslinking agent: Using a rigid-flexible structured bridged methyl citrate compound as raw material, the methyl citrate groups are first saponified in a NaOH / H2O / ethanol reaction system to convert them into the corresponding sodium citrate salt. Then, hydrochloric acid is used to acidify the sodium citrate salt to convert it into citric acid groups, thus obtaining a rigid-flexible structured bridged citric acid crosslinking agent with the following chemical structural formula:

[0044] ;

[0045] Where R is ;

[0046] The glycol monomer is selected from one of tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, heptaethylene glycol, and octaethylene glycol.

[0047] This invention selects representative tetraethylene glycol (n=3), hexaethylene glycol (n=5), and octaethylene glycol (n=7) for research and development experiments:

[0048] Research Experiment 1: Using a method for synthesizing rigid-flexible structured bridged citric acid crosslinking agents, when tetraethylene glycol is used as the glycol monomer, a rigid-flexible structured bridged citric acid crosslinking agent M-4 was synthesized, with the following chemical structural formula:

[0049] ;

[0050] Where R is ;

[0051] The specific preparation process of rigid-flexible structured bridging citric acid crosslinking agent M-4 is as follows:

[0052] (1) Preparation of dicitrate methyl ester type monochlorotriazine intermediate:

[0053] The glassware, including the reaction flask, stir bar, and constant pressure dropping funnel, were placed in a 120℃ oven to dry for 12 hours. After being removed, they were placed in a desiccator to cool to room temperature. The reaction apparatus was quickly assembled, and the double-row tubes were connected. The system was evacuated and purged with nitrogen three times, and the system was kept under inert gas protection throughout the process.

[0054] Add 0.82 g NaH (sodium hydride, 60% mineral oil dispersion) to the reaction flask, add 10 mL of anhydrous n-hexane, stir and let stand, use a syringe to remove the upper n-hexane, repeat washing 3 times to remove mineral oil, and vacuum dry the residual n-hexane through a double-row tube under nitrogen protection.

[0055] Add 20 mL of anhydrous THF (anhydrous tetrahydrofuran), turn on magnetic stirring, and cool the reaction flask in an ice-water bath at 0 °C. Dissolve 4.64 g of methyl citrate in 40 mL of anhydrous THF, transfer the solution to a constant pressure dropping funnel, and slowly add it dropwise into the reaction flask (the dropping process takes about 40 min). During the dropping process, control the system temperature to not exceed 5 °C. After the dropping is complete, stir the reaction at 0 °C for 45 min (hydroxyl deprotonation treatment, during which bubbles can be seen to be generated) to obtain a THF solution of sodium methyl citrate.

[0056] Take another dried reaction flask, reassemble the reaction apparatus and protect it with nitrogen. Add 1.84 g of cyanuric chloride and 20 mL of anhydrous THF to the reaction flask, turn on the magnetic stirrer and stir to dissolve at room temperature for 20 min. Place the reaction flask in an ice-water bath at 0 °C to cool. Slowly add the above sodium citrate methyl ester THF solution to the reaction flask through a constant pressure dropping funnel (the dropping process takes about 60 min). Control the system temperature not to exceed 5 °C during the dropping process. After the dropping is completed, stir the reaction at 0 °C for 1 h. Remove the ice-water bath and let it rise naturally to room temperature (25 °C) and stir the reaction for 6 h. Then raise the temperature to 40 °C and continue stirring the reaction for 2 h. Take samples every 2 h for TLC monitoring (petroleum ether / ethyl acetate = 5:1, v / v).

[0057] After the reaction was completed, the mixture was allowed to cool naturally to room temperature. The reaction flask was then placed back in a 0°C ice-water bath. In a fume hood, saturated ammonium chloride solution was slowly added dropwise to quench the reaction (the dropping rate was controlled at 0.5 mL / min) until no more bubbles were generated. The mixture was then transferred to a separatory funnel and extracted three times with ethyl acetate. The organic phases were combined and washed once quickly with saturated brine pre-cooled to 5°C. The mixture was dried over anhydrous sodium sulfate for 2 hours, filtered, and the solvent was removed by rotary evaporation under reduced pressure.

[0058] The crude product was purified by neutral alumina column chromatography (petroleum ether / ethyl acetate = 8:1 → 3:1 gradient elution, v / v), and dried under vacuum to obtain a dimethyl citrate type monochlorotriazine intermediate.

[0059] The reaction system can be scaled up proportionally according to the amount required for subsequent reactions using the above method to obtain a dimethyl citrate type monochlorotriazine intermediate, which can then be used in subsequent reactions.

[0060] (2) Preparation of rigid-flexible structured bridged methyl citrate compound M-4:

[0061] The glassware, including the reaction flask, stir bar, and constant pressure dropping funnel, were placed in a 120℃ oven to dry for 12 hours. After being removed, they were placed in a desiccator to cool to room temperature. The reaction apparatus was quickly assembled, and the double-row tubes were connected. The system was evacuated and purged with nitrogen three times, and the system was kept under inert gas protection throughout the process.

[0062] Add 0.42 g NaH (sodium hydride, 60% mineral oil dispersion) to the reaction flask, add 10 mL of anhydrous n-hexane, stir and let stand, use a syringe to aspirate the upper n-hexane, repeat washing 3 times to remove mineral oil, and vacuum dry the residual n-hexane through a double-row tube under nitrogen protection.

[0063] Add 10 mL of anhydrous THF, turn on magnetic stirring, and cool the reaction flask in an ice-water bath at 0 °C. Dissolve 0.97 g of tetraethylene glycol in 15 mL of anhydrous THF, transfer the solution to a constant pressure dropping funnel, and slowly add it dropwise into the reaction flask (the dropping process takes about 20 min). During the dropping process, control the system temperature to not exceed 5 °C. After the dropping is complete, stir the reaction at 0 °C for 30 min (hydroxyl group deprotonation treatment, during which bubbles can be seen to be generated) to obtain a THF solution of disodium tetraethylene glycol.

[0064] 5.91 g of dimethyl citrate-type monochlorotriazine intermediate was dissolved in 50 mL of anhydrous THF, transferred to a constant pressure dropping funnel, and slowly added dropwise to the above-mentioned tetraethylene glycol disodium THF solution (the addition process takes about 50 min). During the addition process, the system temperature was controlled not to exceed 5 °C. After the addition was completed, the ice-water bath was removed, and the mixture was naturally heated to room temperature (25 °C) and stirred for 2 h. Then, the temperature was raised to 70 °C and stirred under reflux for 8 h. Samples were taken every 2 h for TLC monitoring (dichloromethane / methanol = 15:1, v / v).

[0065] After the reaction was completed, the mixture was allowed to cool naturally to room temperature. The reaction flask was then placed back in an ice-water bath at 0°C. In a fume hood, saturated ammonium chloride solution was slowly added dropwise to quench the reaction (the dropping rate was controlled at 0.5 mL / min) until no more bubbles were generated. The mixture was then transferred to a separatory funnel and extracted three times with dichloromethane. The organic phases were combined and washed once quickly with saturated brine pre-cooled to 5°C. The mixture was dried over anhydrous sodium sulfate for 2 hours, filtered, and the solvent was removed by rotary evaporation under reduced pressure.

[0066] The crude product was purified by neutral alumina column chromatography (dichloromethane / methanol = 20:1 → 10:1 gradient elution, v / v), and vacuum dried to obtain rigid-flexible structured bridged methyl citrate compound M-4.

[0067] (3) Preparation of rigid-flexible structured bridging citric acid crosslinking agent M-4:

[0068] Prepare 100 mL of 0.6 mol / L NaOH aqueous solution, add it to the reaction flask, and then add 20 mL of anhydrous ethanol as a co-solvent. Stir and mix at room temperature for 10 min.

[0069] Under stirring at room temperature, 5.0 g of rigid-flexible structured bridged methyl citrate compound M-4 was added to the above solution in three batches with an interval of 10 min between each batch. After the addition was completed, the mixture was stirred for 20 min, and then the temperature was raised to 40 °C and stirred for 5 h.

[0070] After the reaction is complete, allow it to cool naturally to room temperature. Place the reaction flask in a 0°C ice-water bath and slowly add 37% concentrated hydrochloric acid dropwise in a fume hood (the dropping rate is controlled at 0.5 mL / min). Stir rapidly while adding the acid and monitor the pH of the system with precision pH paper until the pH stabilizes at 1.5. Stop adding the acid when the pH stabilizes at 1.5 (the system temperature is controlled not to exceed 10°C during the dropping process).

[0071] The reaction solution was transferred to a dialysis bag with a molecular weight cutoff of 500 Da, sealed, and then dialyzed in deionized water for purification. The deionized water was changed every 6 hours, and the dialysis was performed for 36 hours. The last dialysis solution was taken and 0.1 mol / L silver nitrate solution was added for testing. When no white turbidity was produced, it was confirmed that chloride ions had been completely removed.

[0072] The product solution in the dialysis bag was collected, concentrated to 1 / 5 of the original volume by rotary evaporation under reduced pressure, and then freeze-dried for 24 hours to obtain rigid-flexible structured bridging citric acid crosslinking agent M-4.

[0073] The characterization results of the rigid-flexible structured bridging citric acid crosslinking agent M-4 are as follows:

[0074] 1H NMR (D2O, 400MHz) δ: 3.09 (s, 16H), 3.64-3.71 (m, 8H), 3.79-3.82 (t, 4H), 4.36-4.39 (t, 4H);

[0075] The elemental analysis was performed using a Vario EL Ⅲ type elemental analyzer, and the results are as follows:

[0076] Theoretical values: C 41.02%, H 3.99%, N 7.55%;

[0077] Measured values: C 40.95%, H 3.90%, N 7.48%;

[0078] An Agilent 6120 single quadrupole liquid chromatography-mass spectrometry system was used in electrospray ionization (ESI) positive ion mode. + The rigid-flexible structured bridging citric acid crosslinking agent M-4 was analyzed by mass spectrometry, and its chromatographic purity was evaluated by HPLC area normalization method.

[0079] The theoretical average relative molecular mass of the rigid-flexible structured bridging citric acid crosslinking agent M-4 is 1112.78. LC-MS detection results showed that a protonated molecular ion related signal with m / z 1113.78 was observed in the mass spectrum of the corresponding chromatographic peak of the target compound, which is consistent with the [M+H]⁺ ion signal expected based on its theoretical average relative molecular mass, supporting the formation of the target compound M-4. The percentage of the main peak area (chromatographic purity) of M-4 was determined to be 99.7% by HPLC area normalization method.

[0080] Research Experiment 2: Using a method for synthesizing rigid-flexible structured bridged citric acid crosslinking agents, when hexaethylene glycol is used as the glycol monomer, a rigid-flexible structured bridged citric acid crosslinking agent M-6 was synthesized, with the following chemical structural formula:

[0081] ;

[0082] Where R is ;

[0083] The specific preparation process of rigid-flexible structured bridging citric acid crosslinking agent M-6 is as follows:

[0084] (1) The specific experimental steps for preparing the dimethyl citrate type monochlorotriazine intermediate are the same as those for the dimethyl citrate type monochlorotriazine intermediate in Experiment 1 of the Research and Development Project.

[0085] (2) The rigid-flexible structured bridged methyl citrate compound M-6 was prepared. The only difference between the specific experimental steps and those of the rigid-flexible structured bridged methyl citrate compound M-4 in Experiment 1 was that 1.41g of hexaethylene glycol was used instead of 0.97g of tetraethylene glycol.

[0086] (3) The rigid-flexible structured bridged citric acid crosslinking agent M-6 was prepared. The specific experimental steps were different from those of the rigid-flexible structured bridged citric acid crosslinking agent M-4 in Experiment 1 of the R&D project. The only difference was that the rigid-flexible structured bridged citric acid crosslinking agent M-4 was replaced by the rigid-flexible structured bridged citric acid methyl ester compound M-6.

[0087] The characterization results of the rigid-flexible structured bridging citric acid crosslinking agent M-6 are as follows:

[0088] 1 H NMR (D2O, 400MHz) δ: 3.08 (s, 16H), 3.64-3.72 (m, 16H), 3.80-3.83 (t, 4H), 4.34-4.37 (t, 4H);

[0089] The elemental analysis was performed using a Vario EL Ⅲ type elemental analyzer, and the results are as follows:

[0090] Theoretical values: C 42.01%, H 4.36%, N 7.00%;

[0091] Measured values: C 41.93%, H 4.30%, N 6.91%;

[0092] The theoretical average relative molecular mass of the rigid-flexible structured bridging citric acid crosslinking agent M-6 is 1200.88. LC-MS detection results showed that a protonated molecular ion related signal with m / z 1201.90 was observed in the mass spectrum of the corresponding chromatographic peak of the target compound, which is consistent with the [M+H]⁺ ion signal expected based on its theoretical average relative molecular mass, supporting the formation of the target compound M-6. The percentage of the main peak area (chromatographic purity) of M-6 was determined to be 99.5% by HPLC area normalization method.

[0093] Research Experiment 3: Using a method for synthesizing rigid-flexible structured bridged citric acid crosslinking agents, when octaethylene glycol is used as the glycol monomer, a rigid-flexible structured bridged citric acid crosslinking agent M-8 was synthesized, with the following chemical structural formula:

[0094] ;

[0095] Where R is ;

[0096] The specific preparation process of rigid-flexible structured bridging citric acid crosslinking agent M-8 is as follows:

[0097] (1) The specific experimental steps for preparing the dimethyl citrate type monochlorotriazine intermediate are the same as those for the dimethyl citrate type monochlorotriazine intermediate in Experiment 1 of the Research and Development Project.

[0098] (2) The rigid-flexible structured bridged methyl citrate compound M-8 was prepared. The only difference between the specific experimental steps and those of the rigid-flexible structured bridged methyl citrate compound M-4 in Experiment 1 was that 1.85g of octaethylene glycol was used instead of 0.97g of tetraethylene glycol.

[0099] (3) The specific experimental steps of preparing rigid-flexible structured bridged citric acid crosslinking agent M-8 are different from those of rigid-flexible structured bridged citric acid crosslinking agent M-4 in Experiment 1 of the R&D project. The only difference is that rigid-flexible structured bridged citric acid crosslinking agent M-4 is replaced by rigid-flexible structured bridged citric acid methyl ester compound M-8.

[0100] The characterization results of the rigid-flexible structured bridging citric acid crosslinking agent M-8 are as follows:

[0101] 1 H NMR (D2O, 400MHz) δ: 3.09 (s, 16H), 3.63-3.69 (m, 24H), 3.81-3.83 (t, 4H), 4.37-4.40 (t, 4H);

[0102] The elemental analysis was performed using a Vario EL Ⅲ type elemental analyzer, and the results are as follows:

[0103] Theoretical values: C 42.86%, H 4.69%, N 6.52%;

[0104] Measured values: C 42.81%, H 4.60%, N 6.45%;

[0105] The theoretical average relative molecular mass of the rigid-flexible structured bridging citric acid crosslinking agent M-8 is 1288.99. LC-MS detection results showed that a protonated molecular ion-related signal with m / z 1289.98 was observed in the mass spectrum of the corresponding chromatographic peak of the target compound, which is consistent with the [M+H]⁺ ion signal expected based on its theoretical average relative molecular mass, supporting the formation of the target compound M-8. The percentage of the main peak area (chromatographic purity) of M-8 was determined to be 99.7% by HPLC area normalization method.

[0106] Example 1:

[0107] A modified pharmaceutical excipient derived from traditional Chinese medicine polysaccharide fibers, comprising the following raw materials in parts by weight:

[0108] 15 portions of Astragalus polysaccharides (purity >90%);

[0109] 75 parts polyvinyl alcohol (model 1788);

[0110] 5 parts of rigid-flexible structured bridging citric acid crosslinking agent;

[0111] 1000 portions of deionized water;

[0112] Among them, the rigid-flexible structured bridging citric acid crosslinking agent is one of the rigid-flexible structured bridging citric acid crosslinking agents M-4, M-6, and M-8.

[0113] Example 2:

[0114] A method for preparing a modified pharmaceutical excipient made from polysaccharide fibers derived from traditional Chinese medicine includes the following steps:

[0115] Step 1, Raw material pretreatment:

[0116] Astragalus polysaccharide was dried in a vacuum drying oven at 40℃ for 12 hours to remove residual moisture. After removal, it was pulverized and passed through an 80-mesh sieve. It was then sealed and placed in a desiccator to cool for later use. Polyvinyl alcohol 1788 was pulverized and passed through an 80-mesh sieve for later use.

[0117] Step 2, Preparation of composite spinning solution:

[0118] 75 parts by weight of polyvinyl alcohol were added to 700 parts by weight of deionized water and stirred at 90°C for 2 hours (the solution was clear and transparent with no visible particles). The solution was then naturally cooled to room temperature to obtain an aqueous PVA solution.

[0119] Add 15 parts by weight of Astragalus polysaccharide to the remaining 300 parts by weight of deionized water, stir and dissolve at 50°C for 1 hour. After dissolution, filter through a 400-mesh filter cloth to remove trace amounts of insoluble impurities. Collect the filtrate and allow it to cool naturally to room temperature to obtain an aqueous solution of Astragalus polysaccharide.

[0120] The above-mentioned Astragalus polysaccharide aqueous solution was slowly added to the PVA aqueous solution. After the addition was completed, the mixture was stirred and mixed at room temperature for 1 hour to ensure that the two were fully mixed.

[0121] Five parts by weight of rigid-flexible structured bridging citric acid crosslinking agent were added to the above mixed solution, stirred and mixed at room temperature for 30 min, and allowed to stand for degassing for 30 min to obtain the composite spinning solution.

[0122] Step 3: Electrospinning to prepare fiber precursors:

[0123] The composite spinning solution is loaded into the pusher of the electrospinning equipment, a 21G flat-mouth stainless steel needle is installed, and a high-voltage power supply is connected; an aluminum foil-wrapped roller is used as a receiving device, the receiving distance is adjusted to 18cm, and the roller speed is 100r / min.

[0124] The spinning process parameters were set as follows: voltage 18kV, feed speed 0.8mL / h; spinning ambient temperature was controlled at 25℃ and relative humidity at 60%.

[0125] Turn on the high voltage power supply and the propulsion pump, and spin continuously for 4 hours. After spinning, place the fiber membrane collected on the receiving device in a vacuum oven at 30°C for 12 hours to remove residual moisture and obtain a fiber precursor with a thickness of 100μm.

[0126] Step 4, Heat Treatment:

[0127] The fiber precursor was laid flat on a high-temperature resistant tray and placed in a vacuum drying oven. The temperature was slowly increased to 120°C at a rate of 2°C / min, and the mixture was kept at this temperature for 3 hours for vacuum thermal crosslinking treatment to form a stable covalent crosslinked network. After the reaction was completed, the temperature was slowly reduced to room temperature at a rate of 1°C / min to prevent the fiber from shrinking and curling due to sudden temperature changes. Then, the mixture was placed in an environment with a temperature of 25°C and a relative humidity of 60% for 24 hours to equilibrate, thus obtaining a crosslinked Astragalus polysaccharide / polyvinyl alcohol fiber membrane, which is a modified pharmaceutical excipient made from polysaccharide fiber derived from traditional Chinese medicine.

[0128] Among them, when the rigid-flexible structured bridging citric acid crosslinking agents are M-4, M-6, and M-8 respectively, crosslinked Astragalus polysaccharide / polyvinyl alcohol fiber membranes I, II, and III are prepared, namely, Chinese herbal medicine-derived polysaccharide fiber composite modified pharmaceutical excipients I, II, and III.

[0129] Comparative Example 1:

[0130] A medicinal herb-derived polysaccharide fiber composite pharmaceutical excipient a (non-crosslinking blank control), comprising the following raw materials in parts by weight:

[0131] 15 portions of Astragalus polysaccharides (purity >90%);

[0132] 75 parts polyvinyl alcohol (model 1788);

[0133] 1000 portions of deionized water;

[0134] The preparation method of a herbal polysaccharide fiber composite pharmaceutical excipient a is the same as the preparation experiment of herbal polysaccharide fiber composite modified pharmaceutical excipient I, the only difference being that: in step two, the rigid-flexible structured bridging citric acid crosslinking agent M-4 is not added.

[0135] Comparative Example 2:

[0136] A medicinal excipient b, a polysaccharide fiber composite pharmaceutical excipient derived from traditional Chinese medicine (a conventional small molecule citric acid crosslinking control), comprises the following raw materials in parts by weight:

[0137] 15 portions of Astragalus polysaccharides (purity >90%);

[0138] 75 parts polyvinyl alcohol (model 1788);

[0139] 5 parts citric acid;

[0140] 1000 portions of deionized water;

[0141] The preparation method of a herbal polysaccharide fiber composite pharmaceutical excipient b is the same as the preparation experiment of herbal polysaccharide fiber composite modified pharmaceutical excipient I, the only difference being that citric acid is used to replace the rigid-flexible structured bridging citric acid crosslinking agent M-4.

[0142] Performance testing:

[0143] The following performance tests were conducted on the modified pharmaceutical excipients made from polysaccharide fibers derived from traditional Chinese medicine:

[0144] (1) Wet stability test:

[0145] Take a sample and weigh it accurately (M0). Immerse it in PBS buffer (pH=7.4, simulated body fluid environment) at 37℃ and let it stand at a constant temperature for 24 hours. Take out the sample, blot the free liquid on the surface with filter paper, weigh it, and record it as M1.

[0146] After soaking for 24 hours, the sample was rinsed with deionized water and then freeze-dried to constant weight. The weight was recorded as M2.

[0147] Calculate the swelling rate and solubility rate using the following formula:

[0148] 24h swelling rate (%) = [(M1-M0) / M0] × 100%;

[0149] 24h solubility (%) = [(M0-M2) / M0] × 100%;

[0150] (2) Mechanical property test: The tensile test was conducted on a 10mm×50mm sample at a tensile speed of 5mm / min under the conditions of 25℃ and 60%RH using an electronic fiber tensile tester with a spacing length of 20mm. The breaking strength and elongation at break of the sample were recorded.

[0151] (3) Biocompatibility test:

[0152] Cytotoxicity test: Referring to GB / T 16886.5-2017 "Biological evaluation of medical devices - Part 5: In vitro cytotoxicity test", L929 mouse fibroblasts were used to perform CCK-8 assay using the extract method.

[0153] Each group of samples was extracted with cell culture medium at a ratio of 0.1 g / mL in a 37℃, 5% CO2 incubator for 24 h to prepare the extract.

[0154] L929 cells were seeded in 96-well plates (5 × 10⁶ cells per well). 3 Cells / well), after culturing for 24 h, were replaced with sample extract. A negative control group (adding an equal volume of complete culture medium, cell viability defined as 100%) and a blank control group (adding only an equal volume of complete culture medium, cell-free, used to subtract background absorbance) were simultaneously set up. Cultured for another 24 h, then incubated with CCK-8 reagent for 2 h. The absorbance (OD) at 450 nm was measured using a microplate reader. The relative cell viability was calculated using the following formula:

[0155] Cell viability (%) = [(OD) 实验组 -OD 空白对照组 ) / (OD 阴性对照组 -OD 空白对照组 )]×100%;

[0156] Skin irritation test: Referring to GB / T 16886.23-2023 "Biological evaluation of medical devices - Part 23: Irritation test" (this standard is used for the evaluation of irritation / intradermal reaction of skin and other tissues), a rabbit broken skin model was used: broken skin wounds were made on both sides of the spine on the back of rabbits, and each group of samples was covered. Physiological saline was used as a negative control. Skin erythema and edema were observed 72 hours after administration. The irritation degree was scored according to the scoring system specified in this standard.

[0157] The performance test results are shown in Table 1 below.

[0158] Table 1 Performance test results of pharmaceutical excipients modified with polysaccharide fiber from traditional Chinese medicine

[0159] Test Project Excipient I Excipient II Excipient III Comparative Example 1 Comparative Example 2 24h swelling rate (%) 134.8 158.3 176.5 385.2 121.6 24h solubility (%) 5.89 6.41 6.96 34.72 10.18 Fracture strength (MPa) 8.15 7.73 7.20 5.24 8.62 Elongation at break (%) 70.8 89.2 102.5 48.4 25.3 Cell viability (%) 98.5 99.1 98.7 99.3 99.0 Stimulation level Non-irritating Non-irritating Non-irritating Non-irritating Non-irritating

[0160] The following conclusions can be drawn from the analysis of the performance experiment results in Table 1:

[0161] Conclusion 1: Compared with Comparative Example 1 without crosslinking agent, the 24h solubility of the fiber membranes obtained after adding M-4, M-6 or M-8 was significantly reduced, indicating that the crosslinking treatment can reduce the dissolution of fiber membrane components in PBS;

[0162] As the length of the glycol bridging chain in the crosslinking agent increased from M-4 to M-8, the 24-hour solubility of the resulting fiber membrane gradually increased from 5.89% to 6.96%, the tensile strength gradually decreased from 8.15 MPa to 7.20 MPa, while the elongation at break gradually increased from 70.8% to 102.5%. These results indicate that changing the length of the glycol bridging chain can regulate the wet stability and mechanical properties of the resulting fiber membrane.

[0163] Without being constrained by specific theories, it is speculated that the above changes may be related to the alteration of the crosslinking node spacing and the mobility of the crosslinking network segments after the change in glycol chain length. Longer glycol bridging chains can provide greater chain segment mobility, thus improving the elongation and deformation capacity of the fiber membrane; at the same time, the increased effective spacing between crosslinking nodes may lead to corresponding changes in material strength and leaching resistance.

[0164] Meanwhile, the 24-hour swelling rate of the fiber membrane also showed a gradient increasing trend with the increase of glycol bridging chain length. The 24-hour swelling rates of excipients I, II, and III (corresponding to crosslinking agents M-4, M-6, and M-8, respectively) were 134.8%, 158.3%, and 176.5%, respectively, all significantly lower than that of comparative example I (385.2%) without crosslinking agent. This indicates that the construction of the crosslinking network can reduce the water absorption and swelling of the fiber membrane in PBS buffer, and the equilibrium swelling level of the material can be controlled by changing the length of glycol bridging chain to match the liquid absorption function requirements in different scenarios.

[0165] Conclusion 2: The 24-hour swelling rate of the comparative example 2, crosslinked with small molecule citric acid, was 121.6%, and its tensile strength was 8.62 MPa, slightly better than the three groups of samples with bridged crosslinking. However, its 24-hour solubility reached 10.18%, and its elongation at break was only 25.3%, both lower than the three groups of samples with bridged crosslinking. These results indicate that traditional crosslinking with small molecule citric acid may improve the swelling resistance and tensile strength of materials through higher crosslinking density, but it may also lead to problems such as high rigidity of the crosslinking network and limited chain segment mobility, resulting in increased brittleness. Furthermore, small molecule crosslinking agents are more prone to single-end grafting reactions, making it relatively difficult to form a uniform and complete effective crosslinking network. This may be one of the reasons why its dissolution resistance is weaker than that of bridged crosslinking agents.

[0166] Conclusion 3: Under the test conditions set in this experiment, the relative survival rate of L929 cells in all groups was higher than 98%, and no obvious in vitro cytotoxicity was observed.

[0167] Skin irritation test results showed that all samples were non-irritating, and the overall safety initially met the requirements for use as pharmaceutical excipients.

Claims

1. A Chinese herbal medicine-derived polysaccharide fiber composite modified pharmaceutical adjuvant, characterized in that, The herbal polysaccharide fiber composite modified pharmaceutical excipient is a cross-linked Astragalus polysaccharide / polyvinyl alcohol fiber membrane, which is prepared from the following raw materials in parts by weight: 10-20 parts of Astragalus polysaccharide; 70-85 parts polyvinyl alcohol; 3-8 parts of rigid-flexible structured bridging citric acid crosslinking agent; 900-1100 parts deionized water; The chemical structural formula of the rigid-flexible structured bridged citric acid crosslinking agent is as follows: ; wherein R is .

2. The Chinese herbal polysaccharide fiber composite modified pharmaceutical excipient according to claim 1, characterized in that, The purity of the Astragalus polysaccharide is >90%.

3. The Chinese herbal polysaccharide fiber composite modified pharmaceutical excipient according to claim 1, characterized in that, The polyvinyl alcohol is designated as model 1788.

4. A method for preparing a Chinese herbal polysaccharide fiber composite modified pharmaceutical excipient according to any one of claims 1-3, characterized in that, Includes the following steps: Step 1: Vacuum dry, pulverize and sieve the astragalus polysaccharide, and pulverize and sieve the polyvinyl alcohol for later use; Step 2: Add polyvinyl alcohol to 65-75 wt% of the total formula in deionized water, heat and stir to dissolve, and cool to obtain a PVA aqueous solution; add astragalus polysaccharide to the remaining amount of the formula in deionized water, heat and stir to dissolve, filter, and cool to obtain an astragalus polysaccharide aqueous solution; add the astragalus polysaccharide aqueous solution to the PVA aqueous solution and mix well, then add a rigid-flexible structured bridging citric acid crosslinking agent, stir and mix, and let stand to degas to obtain a composite spinning solution; Step 3: Electrospin the composite spinning solution, and after spinning, vacuum dry the collected fiber membrane to obtain the fiber precursor. Step 4: The fiber precursor is thermally cross-linked under vacuum conditions, cooled, and post-treated to obtain a cross-linked Astragalus polysaccharide / polyvinyl alcohol fiber membrane, which is a modified pharmaceutical excipient made from polysaccharide fiber derived from traditional Chinese medicine.

5. The preparation method of a herbal polysaccharide fiber composite modified pharmaceutical excipient according to claim 4, characterized in that, The preparation method of the rigid-flexible structured bridged citric acid crosslinking agent is as follows: Using 1 molar equivalent of cyanuric chloride and 1.95-1.99 molar equivalent of methyl citrate as raw materials, in a NaH / THF reaction system, taking advantage of the difference in the activity of the chlorine groups in cyanuric chloride, a stepwise substitution reaction is carried out between the hydroxyl group of methyl citrate and the two chlorine groups in cyanuric chloride to obtain a dimethyl citrate type monochlorotriazine intermediate. Using 2.01-2.05 molar equivalents of dimethyl citrate-type monochlorotriazine intermediate and 1 molar equivalent of glycol monomer as raw materials, in a NaH / THF reaction system, a rigid-flexible structured bridged methyl citrate compound was obtained by substitution reaction between the hydroxyl group of the glycol monomer and the chlorine group in the dimethyl citrate-type monochlorotriazine intermediate. Using rigid-flexible structured bridging methyl citrate as raw material, the methyl citrate groups are first saponified in a NaOH / H2O / ethanol reaction system to convert them into the corresponding sodium citrate salt. Then, hydrochloric acid is used to acidify the sodium citrate salt to convert it into citric acid groups, thus obtaining a rigid-flexible structured bridging citric acid crosslinking agent.

6. A method for preparing a Chinese herb-derived polysaccharide fiber composite modified pharmaceutical excipient according to claim 5, characterized in that, The glycol monomer is one of tetraethylene glycol, pentaethylene glycol, hexaethylene glycol, heptaethylene glycol, or octaethylene glycol.

7. A method for preparing a Chinese herb-derived polysaccharide fiber composite modified pharmaceutical excipient according to claim 4, characterized in that, In step two: polyvinyl alcohol is stirred and dissolved at 85-95℃ for 1.5-2.5h; astragalus polysaccharide is stirred and dissolved at 45-55℃ for 0.8-1.2h.

8. A method for preparing a Chinese herb-derived polysaccharide fiber composite modified pharmaceutical excipient according to claim 4, characterized in that, The electrospinning process parameters in step three are: voltage 16-20kV, receiving distance 15-20cm, feed speed 0.6-1.0mL / h, ambient temperature 23℃-28℃, and relative humidity 50-60%.

9. A method for preparing a Chinese herb-derived polysaccharide fiber composite modified pharmaceutical excipient according to claim 4, characterized in that, The process parameters for the thermal crosslinking treatment in step four are: heating to 115-125℃ at a rate of 1.5-2.5℃ / min and holding at that temperature for 2.5-4 hours.

10. The preparation method of a herbal polysaccharide fiber composite modified pharmaceutical excipient according to claim 4, characterized in that, The process parameters for cooling and post-treatment in step four are as follows: first, cool down to 23℃-28℃ at a rate of 1-1.5℃ / min, and then place in an environment with a temperature of 23℃-28℃ and a relative humidity of 50-60% for 20-30 hours to equilibrate.